Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2869256 | Annales de Cardiologie et d'Angéiologie | 2010 | 7 Pages |
Abstract
A strategy for glycoprotein IIb/IIIa inhibitors administration in non ST-segment elevation acute coronary syndrome restricted to 4Â very high risk situations may be considered, without evidence for a loss of chance in intermediate risk patients, untreated although eligible for treatment according to the current guidelines.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
J.-L. Georges, C. Charbonnel, R. Convers-Domart, N. Baron, C. Leterme, G. Galuscan, J. Schwob, B. Livarek,